At the 2015 BIO conference in Philadelphia, FierceBiotech Editor-in-Chief John Carroll moderates a discussion on the future of cancer R&D, featuring leaders from AstraZeneca, Juno Therapeutics, Merck, Johnson & Johnson and GlaxoSmithKline.
Anyone expecting one vaccines maker to pull away from the pack by 2020 had better reconsider. The top four companies--Merck, GlaxoSmithKline, Sanofi and Pfizer--are expected to be within less than one percentage point of each other in total market share, a new report says.
GlaxoSmithKline still has big plans in the burgeoning field of cancer drug R&D. And one of the pharma giant's top cancer drug R&D execs says Glaxo is ready to strike new deals to beef up the pipeline as it considers rebuilding a late-stage research effort and new commercial operations to support marketing the most successful drugs to come out of it.
Novartis has had a complicated year: Three months ago, the Swiss drugmaker closed its multipart asset swap with GlaxoSmithKline, sending most of its troubled vaccines business to GSK and taking on the U.K. drugmaker's oncology business.
Researchers in Australia say a compound tested in mice kills the parasite that causes malaria. They hope to move a candidate they estimate would cost around $1 a dose into human clinical trials, according to an abstract published in the journal Nature.
The race for an Ebola vaccine has slowed to a crawl as Big Pharmas GlaxoSmithKline, Merck and Johnson & Johnson struggle to find volunteers who are exposed to enough disease to show whether experimental vaccines actually protect against Ebola infection.
GlaxoSmithKline is placing a $95 million wager on the significance of the "living genome," a term for the noncoding DNA that appear to regulate how genes function in different cells, states of disease and environments. The initiative will lean heavily on computer scientists, who will make up some of the 40 to 80 researchers that will be hired using the Glaxo funds.
The struggling GlaxoSmithKline is committing more than $95 million in cash and added resources over the next 5 years to launch a new nonprofit institute in Seattle that will explore the "living genome" for new insights into the ways that cells function in search of a new generation of drugs to put into the clinic.
A husband-and-wife team of corporate investigators imprisoned in China for illegally obtaining private records of Chinese citizens and selling the information to clients including GlaxoSmithKline were deported on Wednesday, Reuters reported.
Another week, another rumor about the target on GlaxoSmithKline's back. This time, U.K. traders were talking up a different potential takeover--not by Pfizer, but by Johnson & Johnson or Roche.